Clinical Overview
Lurasidone is an atypical antipsychotic indicated for the treatment of schizophrenia in adults and adolescents, and as monotherapy or adjunctive therapy for bipolar I disorder depressive episodes. It offers a favorable metabolic profile compared to many other atypical antipsychotics.
Primary Clinical Applications
Lurasidone is effective for both positive and negative symptoms of schizophrenia and has demonstrated efficacy in treating depressive episodes associated with bipolar I disorder. Its unique receptor profile provides antipsychotic efficacy while minimizing metabolic side effects.
Mechanism and Advantages
Lurasidone antagonizes dopamine D2 and serotonin 5-HT2A receptors while also acting as a antagonist at 5-HT7 receptors. This mechanism contributes to its efficacy in treating both psychotic and mood symptoms with reduced metabolic impact.
Administration Requirements
Lurasidone must be taken with food containing at least 350 calories to ensure adequate absorption. This food requirement is essential for therapeutic efficacy and should be emphasized to patients and caregivers.
Prescribing Information
Dosing & Administration
Schizophrenia – Adults:
- Initial: 40 mg once daily with food (≥350 calories)
- Range: 40-160 mg daily
- Maximum: 160 mg daily
Schizophrenia – Adolescents (13-17 years):
- Initial: 40 mg once daily with food
- Maximum: 80 mg daily
Bipolar I Depression:
- Monotherapy: 20 mg once daily, may increase to 120 mg daily
- Adjunctive therapy: 20 mg once daily, may increase to 120 mg daily
Indications
- Schizophrenia in adults and adolescents (13-17 years)
- Bipolar I disorder, depressive episodes (monotherapy or adjunctive)
Contraindications
- Known hypersensitivity to lurasidone
- Strong CYP3A4 inhibitors (ketoconazole, clarithromycin)
- Strong CYP3A4 inducers (rifampin, St. John’s wort)
Warnings & Precautions
- Boxed Warning: Increased mortality in elderly patients with dementia-related psychosis; increased suicidal thoughts in children, adolescents, and young adults
- Neuroleptic malignant syndrome risk
- Tardive dyskinesia risk with long-term use
- Metabolic changes: Monitor glucose and lipids
- Orthostatic hypotension and syncope
Drug Interactions
- Strong CYP3A4 inhibitors: Contraindicated
- Moderate CYP3A4 inhibitors: Reduce lurasidone dose by half
- Strong CYP3A4 inducers: Contraindicated
- CNS depressants: Enhanced sedation
Adverse Reactions
Common (≥5%):
- Somnolence, akathisia, nausea, parkinsonism, agitation
Metabolic:
- Lower risk of weight gain and metabolic effects compared to other atypicals
Special Populations
- Renal Impairment: Moderate to severe: Maximum 80 mg daily
- Hepatic Impairment: Moderate: Maximum 80 mg daily; Severe: Maximum 40 mg daily
- Pregnancy: Category B – use if benefits outweigh risks
- Food Requirement: Must take with ≥350 calories for absorption
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
